Pulsed priming with the FAK inhibitor narmafotinib enhances both gemcitabine/Abraxane and FOLFIRINOX chemotherapy response in pancreatic cancer
Kendelle Joan Murphy, Cecilia R. Chambers, Daniel A. Reed, Lily M. Channon, Niamh EP Mills, Sophie E McKay, Victoria Lee, Anna E. Howell, Alice M. H. Tran, Max Nobis, Astrid Magenau, Janett Stoehr, Brooke Pereira, Nadia Kuepper, Shona Ritchie, , Paul Timpson
This paper shows that pulsed narmafotinib priming improves chemotherapy response in pancreatic cancer by reducing fibrosis and enhancing treatment efficacy.
bioRxiv · Jul 23, 2026 · PreprintCancer Biology